Is Traws Pharma going out of business?

Traws Pharma, Inc. (TRAW) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Traws Pharma, Inc. (TRAW) scores 16 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 80.26% (YoY)

Five questions, kept separate

Survival - Critical

2-4 mo of estimated runway from 2026-06-30, based on $5.0M of cash and short-term investments against $20.8M of annual burn. Adjusted shares outstanding increased 80.3% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

248.9% burn burden support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 80.26% (YoY)
• FCF margin: -744.44%
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.24y
• Revenue CAGR (3Y): 131.12%
• Price / Sales: 3.0x (see Valuation)
• Price / Earnings: 0.9x (see Valuation)
• Effective Tax Rate: 0.00% (likely tax credits/loss carryforwards)
• Return on Assets: 79.95% (profit not operating-backed)

Read from filings through 2026-08-14.

Price as of 2026-09-07.